CARDIOPROTECTION POTENTIAL IN CORONARY HEART DISEASE TREATMENT
Aim. To investigate effectiveness and safety of trimetazidine MB in the complex treatment of stable angina. In total, 90 patients were examined – 57 women and 33 men aged 48-70 years (mean age 61,4 ± 6,03 years). All participants received trimetazidine MB (Deprenorm MB) for 3 months (35 mg twice per...
Saved in:
| Main Authors: | N. A. Shostak, O. G. Smolenskaya, A. V. Panov, A. A. Klimenko, D. Yu. Andriyashkina, N. A. Tverdova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2009-12-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1401 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New potential of Trimetazidine MB for coronary heart disease treatment in the real-world clinical practice: results of the Russian multi-centre randomised study PERSPECTIVE (Part II)
by: M. G. Bubnova, et al.
Published: (2011-12-01) -
New perspectives in optimizing treatment of coronary heart disease and arterial hypertension patients
by: N. A. Nikolaev
Published: (2008-02-01) -
TRIMETAZIDINE THERAPY INFLUENCE ON HEART RATE VARIABILITY IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
by: M. V. Novikova, et al.
Published: (2014-10-01) -
Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
by: L. V. Kremneva, et al.
Published: (2005-04-01) -
INTERCHANGEABILITY OF MYOCARDIAL CYTOPROTECTORS IN PATIENTS WITH ISCHEMIC HEART DISEASE. DIFFICULT QUESTIONS –SIMPLE SOLUTIONS
by: Zh. M. Sizova
Published: (2015-09-01)